These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z. Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083 [Abstract] [Full Text] [Related]
9. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women. Uretmen S, Gol M, Cimrin D, Irmak E. Eur J Obstet Gynecol Reprod Biol; 2005 Nov 01; 123(1):67-71. PubMed ID: 16051419 [Abstract] [Full Text] [Related]
12. Is heritability a risk factor for postmenopausal osteoporosis? Hansen MA, Hassager C, Jensen SB, Christiansen C. J Bone Miner Res; 1992 Sep 01; 7(9):1037-43. PubMed ID: 1414496 [Abstract] [Full Text] [Related]
13. [The effect of different "coherent"-type therapeutic plans on bone mineral density and on the incidence of vertebral fractures in advanced osteoporosis]. Cristallini S, Pedetti M, Donatelli C, Gregorio F, Filipponi P. Recenti Prog Med; 1993 May 01; 84(5):336-45. PubMed ID: 8390084 [Abstract] [Full Text] [Related]
14. Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis. Verit FF, Geyikli I, Yazgan P, Celik A. Arch Gynecol Obstet; 2006 Jun 01; 274(3):133-7. PubMed ID: 16532321 [Abstract] [Full Text] [Related]
20. [Bone metabolism in primary hypothyroidism in the adult]. Foscolo G, Roiter I, De Menis E, Da Rin G, Legovini P, Conte N. Minerva Endocrinol; 1991 Jun 01; 16(1):7-10. PubMed ID: 1944017 [Abstract] [Full Text] [Related] Page: [Next] [New Search]